Baughman Robert P, Lower Elyse E, Bradley Deborah A, Raymond Lawrence A, Kaufman Adam
Department of Internal Medicine, 1001 Holmes, Eden Ave, University of Cincinnati Medical Center, Cincinnati, OH 45267-0565, USA.
Chest. 2005 Aug;128(2):1062-47. doi: 10.1378/chest.128.2.1062.
Study a tumor necrosis factor receptor antagonist (etanercept) in the treatment of chronic ocular sarcoidosis.
Eighteen patients with ocular sarcoidosis and ongoing inflammation in the eyes. All patients had received at least 6 months of therapy with methotrexate and were currently receiving corticosteroids. Patients were randomized to receive either etanercept, 25 mg subcutaneously twice a week, or placebo in a double-blind randomized trial. Treatment for ocular inflammation with systemic and local corticosteroids at the beginning and end of 6 months of treatment was noted. All patients underwent an ocular examination at the beginning and the end of the study by one ophthalmologist who was unaware of what treatment the patient was receiving.
Three of the patients treated with etanercept and one treated with placebo were being treated with lower doses of corticosteroids by the end of the study. However, three of the etanercept patients and one of the placebo patients required larger doses of corticosteroids by the end of the study. The ophthalmology global assessment improved for two of the etanercept-treated patients and three of the placebo-treated patients.
For most patients, therapy with etanercept was not associated with a significant improvement in their chronic ocular disease.
研究肿瘤坏死因子受体拮抗剂（依那西普）治疗慢性眼部结节病的效果。
18例眼部结节病且眼部存在炎症的患者。所有患者均接受了至少6个月的甲氨蝶呤治疗，目前正在接受皮质类固醇治疗。在一项双盲随机试验中，患者被随机分为两组，分别接受每周两次皮下注射25毫克依那西普或安慰剂治疗。记录治疗6个月开始和结束时全身及局部使用皮质类固醇治疗眼部炎症的情况。所有患者在研究开始和结束时均由一名不知道患者接受何种治疗的眼科医生进行眼部检查。
到研究结束时，接受依那西普治疗的3例患者和接受安慰剂治疗的1例患者正在接受较低剂量的皮质类固醇治疗。然而，到研究结束时，接受依那西普治疗的3例患者和接受安慰剂治疗的1例患者需要更大剂量的皮质类固醇治疗。接受依那西普治疗的2例患者和接受安慰剂治疗的3例患者的眼科综合评估有所改善。
对于大多数患者而言，依那西普治疗并未使其慢性眼部疾病得到显著改善。
Zotero 插件